Monopar Therapeutics (MNPR) Enterprise Value (2016 - 2020)

Monopar Therapeutics' Enterprise Value history spans 5 years, with the latest figure at -$18.0 million for Q3 2020.

  • For Q3 2020, Enterprise Value fell 300.1% year-over-year to -$18.0 million; the TTM value through Sep 2020 reached -$18.0 million, down 300.1%, while the annual FY2019 figure was -$13.2 million, 91.71% down from the prior year.
  • Enterprise Value for Q3 2020 was -$18.0 million at Monopar Therapeutics, down from -$12.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$2.9 million in Q4 2016 and bottomed at -$18.0 million in Q3 2020.
  • The 5-year median for Enterprise Value is -$7.9 million (2018), against an average of -$8.4 million.
  • The largest annual shift saw Enterprise Value skyrocketed 41.0% in 2019 before it plummeted 300.1% in 2020.
  • A 5-year view of Enterprise Value shows it stood at -$2.9 million in 2016, then plummeted by 240.48% to -$9.8 million in 2017, then grew by 29.54% to -$6.9 million in 2018, then crashed by 91.71% to -$13.2 million in 2019, then crashed by 36.09% to -$18.0 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Enterprise Value are -$18.0 million (Q3 2020), -$12.5 million (Q2 2020), and -$12.6 million (Q1 2020).